1. Home
  2. PVL vs CTSO Comparison

PVL vs CTSO Comparison

Compare PVL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permianville Royalty Trust Trust Units

PVL

Permianville Royalty Trust Trust Units

N/A

Current Price

$1.86

Market Cap

57.8M

Sector

Energy

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

N/A

Current Price

$0.77

Market Cap

45.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PVL
CTSO
Founded
2011
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
45.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
PVL
CTSO
Price
$1.86
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
133.3K
67.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
9.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
N/A
$8.91
P/E Ratio
$26.85
N/A
Revenue Growth
N/A
48.53
52 Week Low
$1.30
$0.60
52 Week High
$2.04
$1.39

Technical Indicators

Market Signals
Indicator
PVL
CTSO
Relative Strength Index (RSI) 60.68 54.78
Support Level $1.75 $0.62
Resistance Level $1.88 $0.84
Average True Range (ATR) 0.06 0.04
MACD 0.02 0.01
Stochastic Oscillator 76.56 59.46

Price Performance

Historical Comparison
PVL
CTSO

About PVL Permianville Royalty Trust Trust Units

Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: